Zynerba to price its IPO of 3 million shares between $13.00 and $15.00

Jefferies, Piper Jaffray, Canaccord Genuity, Oppenheimer will assist

By Devika Patel

Knoxville, Tenn., July 23 – Zynerba Pharmaceuticals, Inc. will sell 3 million common shares in its initial public offering with a 30-day greenshoe of 450,000 additional shares, according to a Form S-1/A filed Thursday with the Securities and Exchange Commission. The company has registered up to $51.75 million of stock for the deal, which was announced on June 30.

The shares will be sold at a price expected to fall between $13.00 and $15.00 per share.

Jefferies LLC and Piper Jaffray & Co. are the bookrunners, and Canaccord Genuity Inc. and Oppenheimer & Co. Inc. are the co-managers.

Perceptive Advisors, LLC has indicated an interest in participating.

Proceeds will be used for development, preclinical studies, clinical trials, working capital, research and development and general corporate purposes.

The pharmaceutical company is based in Devon, Pa. The company intends to list its common stock on the Nasdaq under the symbol “ZYNE.”

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.